These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

514 related items for PubMed ID: 35098751

  • 1. Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs.
    Murage MJ, Princic N, Park J, Malatestinic WN, Zhu B, Atiya B, Kern SA, Stenger KB, Sprabery AT, Ogdie A.
    J Manag Care Spec Pharm; 2022 Feb; 28(2):206-217. PubMed ID: 35098751
    [Abstract] [Full Text] [Related]

  • 2. Comparison of Health Care Costs Among Patients with Psoriasis Initiating Ixekizumab, Secukinumab, or Adalimumab.
    Blauvelt A, Shi N, Zhu B, Burge R, Malatestinic WN, Lin CY, Lew CR, Zimmerman NM, Goldblum OM, Murage MJ.
    J Manag Care Spec Pharm; 2019 Dec; 25(12):1366-1376. PubMed ID: 31778621
    [Abstract] [Full Text] [Related]

  • 3. Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.
    Rubin DT, Mittal M, Davis M, Johnson S, Chao J, Skup M.
    J Manag Care Spec Pharm; 2017 Aug; 23(8):859-867. PubMed ID: 28737994
    [Abstract] [Full Text] [Related]

  • 4. Patient Characteristics, Health Care Resource Utilization, and Costs Associated with Treatment-Regimen Failure with Biologics in the Treatment of Psoriasis.
    Foster SA, Zhu B, Guo J, Nikai E, Ojeh C, Malatestinic W, Goldblum O, Kornberg LJ, Wu JJ.
    J Manag Care Spec Pharm; 2016 Apr; 22(4):396-405. PubMed ID: 27023693
    [Abstract] [Full Text] [Related]

  • 5. Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending.
    Brixner D, Rubin DT, Mease P, Mittal M, Liu H, Davis M, Ganguli A, Fendrick AM.
    J Manag Care Spec Pharm; 2019 Jul; 25(7):770-779. PubMed ID: 31081461
    [Abstract] [Full Text] [Related]

  • 6. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis.
    Wu JJ, Pelletier C, Ung B, Tian M, Khilfeh I, Curtis JR.
    Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018
    [Abstract] [Full Text] [Related]

  • 7. Treatment Patterns Among Patients with Psoriatic Arthritis Treated with a Biologic in the United States: Descriptive Analyses from an Administrative Claims Database.
    Walsh JA, Adejoro O, Chastek B, Palmer JB, Hur P.
    J Manag Care Spec Pharm; 2018 Jul; 24(7):623-631. PubMed ID: 29952704
    [Abstract] [Full Text] [Related]

  • 8. Sustained long-term benefits of patient support program participation in immune-mediated diseases: improved medication-taking behavior and lower risk of a hospital visit.
    Fendrick AM, Brixner D, Rubin DT, Mease P, Liu H, Davis M, Mittal M.
    J Manag Care Spec Pharm; 2021 Aug; 27(8):1086-1095. PubMed ID: 33843252
    [Abstract] [Full Text] [Related]

  • 9. Effectiveness and Costs Among Rheumatoid Arthritis Patients Treated with Targeted Immunomodulators Using Real-World U.S. Data.
    Gharaibeh M, Bonafede M, McMorrow D, Hernandez EJM, Stolshek BS.
    J Manag Care Spec Pharm; 2020 Aug; 26(8):1039-1049. PubMed ID: 32715967
    [Abstract] [Full Text] [Related]

  • 10. Characteristics and Medication Use of Psoriasis Patients Who May or May Not Qualify for Randomized Controlled Trials.
    Malatestinic W, Nordstrom B, Wu JJ, Goldblum O, Solotkin K, Lin CY, Kistler K, Fraeman K, Johnston J, Hawley LL, Sicignano N, Araujo A.
    J Manag Care Spec Pharm; 2017 Mar; 23(3):370-381. PubMed ID: 28230450
    [Abstract] [Full Text] [Related]

  • 11. Early Real-World Experience of Tofacitinib for Psoriatic Arthritis: Data from a United States Healthcare Claims Database.
    Mease PJ, Young P, Gruben D, Fallon L, Germino R, Kavanaugh A.
    Adv Ther; 2022 Jun; 39(6):2932-2945. PubMed ID: 35482248
    [Abstract] [Full Text] [Related]

  • 12. Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies.
    Schwedt TJ, Lee J, Knievel K, McVige J, Wang W, Wu Z, Gillard P, Shah D, Blumenfeld AM.
    J Manag Care Spec Pharm; 2023 Oct; 29(10):1119-1128. PubMed ID: 37776119
    [Abstract] [Full Text] [Related]

  • 13. Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis.
    Sauer BC, Teng CC, He T, Leng J, Lu CC, Walsh JA, Shah N, Harrison DJ, Tang DH, Cannon GW.
    J Med Econ; 2016 Oct; 19(1):34-43. PubMed ID: 26337538
    [Abstract] [Full Text] [Related]

  • 14. A Retrospective Cohort Study Comparing Utilization and Costs of Biologic Therapies and JAK Inhibitor Therapy Across Four Common Inflammatory Indications in Adult US Managed Care Patients.
    Chastek B, White J, Van Voorhis D, Tang D, Stolshek BS.
    Adv Ther; 2016 Apr; 33(4):626-42. PubMed ID: 26970958
    [Abstract] [Full Text] [Related]

  • 15. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
    Wu JJ, Pelletier C, Ung B, Tian M.
    J Med Econ; 2019 Apr; 22(4):365-371. PubMed ID: 30652520
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of Real-World Experience with Tofacitinib Compared with Adalimumab, Etanercept, and Abatacept in RA Patients with 1 Previous Biologic DMARD: Data from a U.S. Administrative Claims Database.
    Harnett J, Gerber R, Gruben D, Koenig AS, Chen C.
    J Manag Care Spec Pharm; 2016 Dec; 22(12):1457-1471. PubMed ID: 27882833
    [Abstract] [Full Text] [Related]

  • 17. Economic Burden of Patients with Inadequate Response to Targeted Immunomodulators for Rheumatoid Arthritis.
    Strand V, Tundia N, Song Y, Macaulay D, Fuldeore M.
    J Manag Care Spec Pharm; 2018 Apr; 24(4):344-352. PubMed ID: 29578852
    [Abstract] [Full Text] [Related]

  • 18. Adherence, Persistence, and Expenditures for High-Cost Anti-Inflammatory Drugs in Rheumatoid Arthritis: An Exploratory Study.
    Khilfeh I, Guyette E, Watkins J, Danielson D, Gross D, Yeung K.
    J Manag Care Spec Pharm; 2019 Apr; 25(4):461-467. PubMed ID: 30917076
    [Abstract] [Full Text] [Related]

  • 19. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
    Wu N, Lee YC, Shah N, Harrison DJ.
    Clin Ther; 2014 Aug 01; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
    [Abstract] [Full Text] [Related]

  • 20. Treatment Patterns and Costs in Biologic DMARD-Naive Patients with Rheumatoid Arthritis Initiating Etanercept or Adalimumab with or Without Methotrexate.
    Tkacz J, Gharaibeh M, DeYoung KH, Wilson K, Collier D, Oko-Osi H.
    J Manag Care Spec Pharm; 2020 Mar 01; 26(3):285-294. PubMed ID: 32105179
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.